A Phase 1 interventional study of Humalog and Humulin-R in Diabetes Mellitus, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-26.
Sponsored by Halozyme Therapeutics · Phase 1, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Insulin Lispro in Diabetes Mellitus — 1 open to participants now, 1 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus.
Among the 25 studies testing Insulin Lispro in Diabetes Mellitus, this one is the 16th largest by enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2007, is one of 2 in phase 1, and was the 12th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →1 of the 25 studies testing Insulin Lispro in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 18–99
By country, each count listing its studies:
Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 7 · Phase 4 9
First in 2002; this study’s year is marked. 6 started in 2007.
This study's enrollment of 26 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 60 across the 24 interventional studies. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 25 have an industry lead sponsor. The 10 most frequent:
Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Halozyme Therapeutics has 3 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing Insulin Lispro in Diabetes Mellitus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of Humalog (insulin lispro) or Humulin-R (recombinant human insulin) when administered as a single subcutaneous (SC) injection of 20 units (U) with or without coadministration of recombinant human hyaluronidase PH20 (rHuPH20).
The study hypothesizes that the time required to reach maximum insulin concentration (tmax) when insulin is administered with rHuPH20 will be comparable or shorter than the time required without rHuPH20.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Humalog first, then Humalog + recombinant human hyaluronidase PH20 (rHuPH20) A single subcutaneous (SC) injection of 20 units (U) Humalog on Day 1 of the study, followed by a single SC injection of 20 U Humalog + 300 U rHuPH20 after a washout period of at least 6 days
Drug: Humalog · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Humalog + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humalog A single subcutaneous (SC) injection of 20 units (U) Humalog + 300 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humalog after a washout period of at least 6 days
Drug: Humalog · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Humulin-R (recombinant human insulin) first, then Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20) A single subcutaneous (SC) injection of 20 units (U) Humulin-R on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R + 240 U rHuPH20 after a washout period of at least 6 days
Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Humulin-R (recombinant human insulin) + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humulin-R A single subcutaneous (SC) injection of 20 units (U) Humulin-R + 240 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R after a washout period of at least 6 days
Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Time to Maximum Serum Insulin Concentration (Tmax)
Time to maximum serum insulin concentration (tmax) values for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from 3 milliliter (mL) blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Maximum Serum Insulin Concentration (Cmax)
Maximum serum insulin concentration (Cmax) values for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from 3 milliliter (mL) blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Area Under the Serum Concentration-Time Curve From Time Zero to the Time Required to Reach Endogenous Plasma Glucose Levels (AUC[0-t'])
Area under the serum concentration-time curve from time zero to the time required to reach endogenous plasma glucose levels (AUC\[0-t'\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from 3 milliliter (mL) blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Area Under the Concentration-Time Curve From Time 0 to Time to Reach Maximum Concentration (Tmax) for Serum Insulin With Recombinant Human Hyaluronidase PH20 (rHuPH20) (AUC[0-tmaxPH20])
Area under the concentration-time curve from time 0 to time to reach maximum concentration (tmax) for serum insulin (Humalog or Humulin-R) with recombinant human hyaluronidase (rHuPH20) (AUC\[0-tmaxPH20\]) for participants who received Humalog or Humulin-R and with rHuPH20 were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment and every 3 min from min 0 through 48 for Stage 1 and, and every 3 min from min 0 through 68 for Stage 2 during the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
Time frame: Predose and up to 48 minutes postdose during Stage 1, or up to 68 minutes postdose during Stage 2
Relative Bioavailability (Area Under the Curve [AUC] for Insulin + Recombinant Human Hyaluronidase [rHuPH20] / AUC for Insulin Alone)
Relative bioavailability was determined by dividing the baseline-corrected geometric mean of the area under the curve (AUC) for insulin (ins) (Humalog or Humulin-R) with recombinant human hyaluronidase PH20 (rHuPH20) by the baseline-corrected geometric mean of the AUC for insulin alone (AUC\[insulin+rHuPH20\]/AUC\[insulin\]). Bioavailability values for participants who received Humalog or Humulin-R and rHuPH20 were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Time to Maximum Glucose Infusion Rate (tGIR[Max])
Time to maximal effect for glucose infusion rate (tGIR\[max\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from blood samples obtained every 3 minutes during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Time to Early Half-Maximal Effect for Glucose Infusion Rate (tGIR[early50%])
Time to early half-maximal effect for glucose infusion rate (tGIR\[early50%\]) for participants who were randomized to Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Time to Late Half-Maximal Effect for Glucose Infusion Rate (tGIR[late50%])
Time to late half-maximal effect for glucose infusion rate (tGIR\[late50%\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period. Because the study was only 360 minutes in duration, there was not sufficient time for regular human insulin to show an effect and therefore tGIR(late50%) could not be calculated for participants receiving Humulin-R alone.
Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Maximum Glucose Infusion Rate (GIR[Max])
Maximum glucose infusion rate (GIR\[max\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Area Under the Glucose Infusion Rate Curve From 0 to 60 Minutes After Injection (AUC[GIR{0-60}])
The area under the curve for the glucose infusion rate from minutes (min) 0 to 60 after injection (AUC\[GIR{0-60}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment and every 3 min from min 0 through 60 during the clamp procedure. Means were calculated using analysis of variance with fixed of participant, sequence within participant, treatment, and period.
Time frame: Predose and up to 60 minutes postdose during Stage 1 or Stage 2
Area Under the Glucose Infusion Rate Curve From 0 to 120 Minutes After Injection (AUC[GIR{0-120}])
The area under the glucose infusion rate curve from minutes 0 to 120 after injection (AUC\[GIR{0-120}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, and every 15 min from min 60 through 120 during the clamp. Means were calculated using analysis of variance with fixed effects of participant, sequence within participant, treatment, and period.
Time frame: Predose and up to 120 minutes postdose during Stage 1 or Stage 2
Area Under the Glucose Infusion Rate Curve From 0 to 180 Minutes After Injection (AUC[GIR{0-180}])
The area under the curve for the glucose infusion rate from minutes (min) 0 to 180 after injection (AUC\[GIR{0-180}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment, every 3 min from min 0 through 60, and every 15 min from min 60 through 180 during the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
Time frame: Predose and up to 180 minutes postdose during Stage 1 or Stage 2
Area Under the Glucose Infusion Rate Curve From 0 to 240 Minutes After Injection (AUC[GIR{0-240}])
The area the glucose infusion rate curve from minutes (min) 0 to 240 after injection (AUC\[GIR{0-240}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 to 240 during the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
Time frame: Predose up to 240 minutes postdose during Stage 1 or Stage 2
Area Under the Glucose Infusion Rate Curve From 0 to 360 Minutes After Injection (AUC[GIR{0-360}])
The area under glucose infusion rate curve from minutes (min) 0 to 360 after injection (AUC\[GIR{0-360}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 to 360 during the clamp. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2
| Milestone | Stage 1: Humalog First, Then Humalog + rHuPH20 | Stage 1: Humalog + rHuPH20 First, Then Humalog | Stage 2: Humulin-R First, Then Humulin-R + rHuPH20 | Stage 2: Humulin-R + rHuPH20 First, Then Humulin-R |
|---|---|---|---|---|
| Started | 6 | 6 | 7 | 7 |
| Received at least 1 dose of study drug | 6 | 6 | 7 | 7 |
| Completed | 6 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Milestone | Stage 1: Humalog First, Then Humalog + rHuPH20 | Stage 1: Humalog + rHuPH20 First, Then Humalog | Stage 2: Humulin-R First, Then Humulin-R + rHuPH20 | Stage 2: Humulin-R + rHuPH20 First, Then Humulin-R |
|---|---|---|---|---|
| Started | 6 | 6 | 7 | 6 |
| Completed | 6 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Stage 1: Humalog First, Then Humalog + rHuPH20 | Stage 1: Humalog + rHuPH20 First, Then Humalog | Stage 2: Humulin-R First, Then Humulin-R + rHuPH20 | Stage 2: Humulin-R + rHuPH20 First, Then Humulin-R |
|---|---|---|---|---|
| Started | 6 | 6 | 7 | 6 |
| Completed | 6 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Stage 1: Humalog First, Then Humalog + rHuPH20 | Stage 1: Humalog + rHuPH20 First, Then Humalog | Stage 2: Humulin-R First, Then Humulin-R + rHuPH20 | Stage 2: Humulin-R + rHuPH20 First, Then Humulin-R |
|---|---|---|---|---|
| Started | 6 | 6 | 7 | 6 |
| Completed | 6 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
Time to maximum serum insulin concentration (tmax) values for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from 3 milliliter (mL) blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
| Minutes | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Time to Maximum Serum Insulin Concentration (Tmax) | 97.5 ± 35.9 | 48.0 ± 7.99 | 163 ± 51.5 | 67.8 ± 19.1 |
Maximum serum insulin concentration (Cmax) values for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from 3 milliliter (mL) blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
| Picomoles per liter | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Maximum Serum Insulin Concentration (Cmax) | 680 ± 361 | 1290 ± 471 | 390 ± 137 | 944 ± 257 |
Time to maximal effect for glucose infusion rate (tGIR\[max\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from blood samples obtained every 3 minutes during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
| Minutes | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Time to Maximum Glucose Infusion Rate (tGIR[Max]) | 193 ± 58.2 | 114 ± 43.0 | 253 ± 61.8 | 165 ± 51.2 |
Time to early half-maximal effect for glucose infusion rate (tGIR\[early50%\]) for participants who were randomized to Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
| Minutes | Stage 1. Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Time to Early Half-Maximal Effect for Glucose Infusion Rate (tGIR[early50%]) | 72.3 ± 16.6 | 43.8 ± 15.1 | 104 ± 33.3 | 47.4 ± 13.1 |
Time to late half-maximal effect for glucose infusion rate (tGIR\[late50%\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period. Because the study was only 360 minutes in duration, there was not sufficient time for regular human insulin to show an effect and therefore tGIR(late50%) could not be calculated for participants receiving Humulin-R alone.
| Minutes | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|
| Time to Late Half-Maximal Effect for Glucose Infusion Rate (tGIR[late50%]) | 324 ± 32.9 | 275 ± 48.0 | 282 ± 68.0 |
Area under the serum concentration-time curve from time zero to the time required to reach endogenous plasma glucose levels (AUC\[0-t'\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from 3 milliliter (mL) blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
| Picomoles per liter times minutes | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Area Under the Serum Concentration-Time Curve From Time Zero to the Time Required to Reach Endogenous Plasma Glucose Levels (AUC[0-t']) | 116000 ± 23000 | 133000 ± 21800 | 91400 ± 25700 | 137000 ± 32800 |
Area under the concentration-time curve from time 0 to time to reach maximum concentration (tmax) for serum insulin (Humalog or Humulin-R) with recombinant human hyaluronidase (rHuPH20) (AUC\[0-tmaxPH20\]) for participants who received Humalog or Humulin-R and with rHuPH20 were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment and every 3 min from min 0 through 48 for Stage 1 and, and every 3 min from min 0 through 68 for Stage 2 during the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
| Picomoles per liter times minutes | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time 0 to Time to Reach Maximum Concentration (Tmax) for Serum Insulin With Recombinant Human Hyaluronidase PH20 (rHuPH20) (AUC[0-tmaxPH20]) | 9530 ± 10500 | 27900 ± 14300 | 8780 ± 3010 | 34800 ± 9150 |
Relative bioavailability was determined by dividing the baseline-corrected geometric mean of the area under the curve (AUC) for insulin (ins) (Humalog or Humulin-R) with recombinant human hyaluronidase PH20 (rHuPH20) by the baseline-corrected geometric mean of the AUC for insulin alone (AUC\[insulin+rHuPH20\]/AUC\[insulin\]). Bioavailability values for participants who received Humalog or Humulin-R and rHuPH20 were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
| Ratio of AUC(ins+rHuPH20)/AUC(ins alone) | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|
| Relative Bioavailability (Area Under the Curve [AUC] for Insulin + Recombinant Human Hyaluronidase [rHuPH20] / AUC for Insulin Alone) | 1.18 ± 0.221 | 1.57 ± 0.406 |
Maximum glucose infusion rate (GIR\[max\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
| Milligrams per kilogram per minute | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Maximum Glucose Infusion Rate (GIR[Max]) | 8.11 ± 4.48 | 8.57 ± 4.24 | 7.82 ± 2.52 | 10.5 ± 3.89 |
The area under the curve for the glucose infusion rate from minutes (min) 0 to 60 after injection (AUC\[GIR{0-60}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment and every 3 min from min 0 through 60 during the clamp procedure. Means were calculated using analysis of variance with fixed of participant, sequence within participant, treatment, and period.
| Grams per kilogram | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Area Under the Glucose Infusion Rate Curve From 0 to 60 Minutes After Injection (AUC[GIR{0-60}]) | 82.8 ± 51.9 | 167 ± 81.0 | 74.3 ± 40.4 | 180 ± 57.7 |
The area under the glucose infusion rate curve from minutes 0 to 120 after injection (AUC\[GIR{0-120}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, and every 15 min from min 60 through 120 during the clamp. Means were calculated using analysis of variance with fixed effects of participant, sequence within participant, treatment, and period.
| Grams per kilogram | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Area Under the Glucose Infusion Rate Curve From 0 to 120 Minutes After Injection (AUC[GIR{0-120}]) | 393 ± 242 | 597 ± 278 | 281 ± 123 | 637 ± 216 |
The area under the curve for the glucose infusion rate from minutes (min) 0 to 180 after injection (AUC\[GIR{0-180}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment, every 3 min from min 0 through 60, and every 15 min from min 60 through 180 during the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
| Grams per kilogram | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Area Under the Glucose Infusion Rate Curve From 0 to 180 Minutes After Injection (AUC[GIR{0-180}]) | 801 ± 420 | 1040 ± 501 | 604 ± 262 | 1150 ± 348 |
The area the glucose infusion rate curve from minutes (min) 0 to 240 after injection (AUC\[GIR{0-240}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 to 240 during the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
| Grams per kilogram | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Area Under the Glucose Infusion Rate Curve From 0 to 240 Minutes After Injection (AUC[GIR{0-240}]) | 1240 ± 618 | 1430 ± 706 | 1010 ± 411 | 1630 ± 467 |
The area under glucose infusion rate curve from minutes (min) 0 to 360 after injection (AUC\[GIR{0-360}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 to 360 during the clamp. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.
| Grams per kilogram | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Area Under the Glucose Infusion Rate Curve From 0 to 360 Minutes After Injection (AUC[GIR{0-360}]) | 1940 ± 963 | 1930 ± 988 | 1860 ± 672 | 2260 ± 611 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1: Humalog Alone | — | 0/12 (0%) | 3/12 (25%) |
| Stage 1: Humalog + rHuPH20 | — | 0/12 (0%) | 3/12 (25%) |
| Stage 2: Humulin-R Alone | — | 0/13 (0%) | 2/13 (15.4%) |
| Stage 2: Humulin-R + rHuPH20 | — | 0/14 (0%) | 3/14 (21.4%) |
| Event | Stage 1: Humalog Alone | Stage 1: Humalog + rHuPH20 | Stage 2: Humulin-R Alone | Stage 2: Humulin-R + rHuPH20 |
|---|---|---|---|---|
| Infusion site painGeneral disorders | 1/12 | 3/12 | 0/13 | 1/14 |
| DysgeusiaNervous system disorders | 1/12 | 0/12 | 0/13 | 0/14 |
| HeadacheNervous system disorders | 1/12 | 0/12 | 0/13 | 0/14 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/12 | 0/12 | 1/13 | 0/14 |
| Injection site pruritusGeneral disorders | 0/12 | 0/12 | 1/13 | 0/14 |
| HematomaVascular disorders | 0/12 | 0/12 | 1/13 | 0/14 |
| Infusion site reactionGeneral disorders | 0/12 | 0/12 | 0/13 | 1/14 |
| Influenza-like illnessGeneral disorders | 0/12 | 0/12 | 0/13 | 1/14 |
| Chest discomfortGeneral disorders | 0/12 | 0/12 | 0/13 | 1/14 |
All participants who received at least 1 dose of Humalog or Humulin-R with or without rHuPH20.
| Age, Continuous(years) | Stage 1: Humalog Alone or Humalog + rHuPH20 | Stage 2: Humulin-R Alone or Humulin-R + rHuPH20 | Total |
|---|---|---|---|
| Mean | 37.7 ± 7.8 | 36.7 ± 8.9 | 37.2 ± 8.3 |
| Sex: Female, Male(Participants) | Stage 1: Humalog Alone or Humalog + rHuPH20 | Stage 2: Humulin-R Alone or Humulin-R + rHuPH20 | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 12 | 14 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Stage 1: Humalog Alone or Humalog + rHuPH20 | Stage 2: Humulin-R Alone or Humulin-R + rHuPH20 | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 10 | 19 |
| Not Hispanic or Latino | 3 | 4 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Stage 1: Humalog Alone or Humalog + rHuPH20 | Stage 2: Humulin-R Alone or Humulin-R + rHuPH20 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 3 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 5 |
| White | 7 | 11 | 18 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Stage 1: Humalog Alone or Humalog + rHuPH20 | Stage 2: Humulin-R Alone or Humulin-R + rHuPH20 | Total |
|---|---|---|---|
| United States | 12 | 14 | 26 |
The record gives a start of Dec 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 6 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Lispro · Insulin, Regular, Human